Effects of omega 3 fatty acids supplementation in behavior and non-neurodegenerative neuropsychiatric disorders (Q34275382)

1 August 2017

Effects of omega 3 fatty acids supplementation in behavior and non-neurodegenerative neuropsychiatric disorders (English)

1 reference

Elena Rodríguez-Rodríguez

1 August 2017

0 references

1 reference

1 reference

ORCID Public Data File 2021

author name string

R M Ortega

series ordinal

1

1 reference

1 August 2017

E Rodríguez-Rodríguez

series ordinal

2

1 reference

1 August 2017

A M López-Sobaler

series ordinal

3

1 reference

1 August 2017

language of work or name

1 reference

1 June 2012

1 reference

British Journal of Nutrition

1 August 2017

1 reference

1 August 2017

107 Suppl 2

1 reference

1 August 2017

S261-70

1 reference

Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study

1 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

A placebo-controlled cross-over trial of adjunctive EPA in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Omega-3 fatty acids (fish-oil) and depression-related cognition in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Clinical characteristics and serum essential fatty acid levels in hyperactive children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

A lack of essential fatty acids as a possible cause of hyperactivity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Placebo response in studies of major depression: variable, substantial, and growing

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Eicosapentaenoic acid as an add-on to antidepressant medication for co-morbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

The efficacy of n-3 fatty acids DHA and EPA (fish oil) for perinatal depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Behavioural changes and psychological symptoms in dementia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Current approaches to management of depression in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Factors associated with depression in Parkinson's disease: a cross-sectional study in a Polish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Treatment of depression in diabetes: impact on mood and medical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Marine omega-3 fatty acids and mood disorders--linking the sea and the soul. 'Food for Thought' I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Fat food for a bad mood. Could we treat and prevent depression in Type 2 diabetes by means of omega-3 polyunsaturated fatty acids? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Omega-3 Treatment of Childhood Depression: A Controlled, Double-Blind Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

7 January 2021

Omega-3 Fatty Acids as a Treatment for Perinatal Depression: Randomized Double-Blind Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

7 January 2021

Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

7 January 2021

Omega-3 fatty acids and neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

7 January 2021

Long-chain polyunsaturated fatty acids, pregnancy, and pregnancy outcome

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

7 January 2021

A Meta-Analytic Review of Double-Blind, Placebo-Controlled Trials of Antidepressant Efficacy of Omega-3 Fatty Acids

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

7 January 2021

A Double-Blind, Placebo-Controlled Study of the Omega-3 Fatty Acid Docosahexaenoic Acid in the Treatment of Major Depression

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

7 January 2021

Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

7 January 2021

Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS000711451200164X

7 January 2021

10.1017/S000711451200164X

Identifiers

DOI

1 reference

1 August 2017

1 reference